Literature DB >> 2839689

Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

T Sairenji1, G Bertoni, M M Medveczky, P G Medveczky, Q V Nguyen, R E Humphreys.   

Abstract

Antibody-mediated inhibition of Epstein-Barr virus (EBV) release from the EBV-productive cell lines P3HR-1 and B95-8 was probed with two monoclonal antibodies (MAbs), 72A1 and 2L10, which immunoprecipitated the same EBV membrane antigen (MA) gp350/220 found with the 1B6 MAb with which inhibition of EBV release from P3HR-1 cells was first described. These three MAbs were not equivalent in either MA reactivities or functional effects, reflecting the variable expression of different epitopes of gp350/220. 1B6 recognized MA on P3HR-1 cells, which expressed predominately the gp220 form of MA. 1B6 did not recognize (or barely recognized) a determinant on B95-8 cells. MAbs 2L10 and 72A1 reacted as well with B95-8 cells as they did with P3HR-1 cells. MAbs 1B6 and 2L10 neutralized neither P3HR-1 nor B95-8 virus, but 72A1 neutralized both viruses. MAbs 1B6 and 72A1 inhibited P3HR-1 virus release, as measured by the assay for infectious virus and by DNA hybridization analysis of released virus, but 2L10 had no such activity. 72A1 (but not 1B6) inhibited release of EBV from B95-8 cells. These experiments pointed to the presence of three different epitopes on gp350/220, identified with the respective MAbs and having varying involvement in virus neutralization and virus release inhibition.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839689      PMCID: PMC253691          DOI: 10.1128/JVI.62.8.2614-2621.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.

Authors:  B C Strnad; T Schuster; R Klein; R F Hopkins; T Witmer; R H Neubauer; H Rabin
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

2.  Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences.

Authors:  C M Edson; D A Thorley-Lawson
Journal:  J Virol       Date:  1981-07       Impact factor: 5.103

3.  Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.

Authors:  D A Thorley-Lawson; C A Poodry
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

4.  Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein.

Authors:  L F Qualtiere; R Chase; G R Pearson
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

5.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

6.  Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs.

Authors:  G W Bornkamm; H Delius; U Zimber; J Hudewentz; M A Epstein
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

7.  Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides.

Authors:  J R North; A J Morgan; M A Epstein
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

8.  Epstein-Barr virus strain- and group-specific antigenic determinants detected by monoclonal antibodies.

Authors:  N Mueller-Lantzsch; B Georg-Fries; H Herbst; H zur Hausen; D G Braun
Journal:  Int J Cancer       Date:  1981-09-15       Impact factor: 7.396

9.  Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody.

Authors:  G Miller; L Heston; G Hoffman
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

10.  Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye.

Authors:  T Sairenji; Y Hinuma
Journal:  Int J Cancer       Date:  1980-09-15       Impact factor: 7.396

View more
  8 in total

1.  Subcellular distribution and life cycle of Epstein-Barr virus in keratinocytes of oral hairy leukoplakia.

Authors:  J P Rabanus; D Greenspan; V Petersen; U Leser; H Wolf; J S Greenspan
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

2.  Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.

Authors:  M T Bejarano; M G Masucci; A Morgan; B Morein; G Klein; E Klein
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

3.  A virus-like particle-based Epstein-Barr virus vaccine.

Authors:  Romana Ruiss; Simon Jochum; Gerhard Wanner; Gilbert Reisbach; Wolfgang Hammerschmidt; Reinhard Zeidler
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

4.  Retrieval of human cytomegalovirus glycoprotein B from the infected cell surface for virus envelopment.

Authors:  K Radsak; M Eickmann; T Mockenhaupt; E Bogner; H Kern; A Eis-Hübinger; M Reschke
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 5.  Epstein-barr virus vaccines.

Authors:  Jeffrey I Cohen
Journal:  Clin Transl Immunology       Date:  2015-01-23

6.  Epstein-Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease.

Authors:  Keiko Nagata; Keisuke Kumata; Yuji Nakayama; Yukio Satoh; Hirotsugu Sugihara; Sayuri Hara; Michiko Matsushita; Satoshi Kuwamoto; Masako Kato; Ichiro Murakami; Kazuhiko Hayashi
Journal:  Viral Immunol       Date:  2017-03-23       Impact factor: 2.257

7.  Presence of Epstein-Barr virus-infected B lymphocytes with thyrotropin receptor antibodies on their surface in Graves' disease patients and in healthy individuals.

Authors:  Keiko Nagata; Katsumi Higaki; Yuji Nakayama; Hiromi Miyauchi; Yui Kiritani; Kyosuke Kanai; Michiko Matsushita; Takeshi Iwasaki; Hirotsugu Sugihara; Satoshi Kuwamoto; Masako Kato; Ichiro Murakami; Eiji Nanba; Hiroshi Kimura; Kazuhiko Hayashi
Journal:  Autoimmunity       Date:  2014-01-28       Impact factor: 2.815

8.  Epstein-Barr Virus Lytic Reactivation Induces IgG4 Production by Host B Lymphocytes in Graves' Disease Patients and Controls: A Subset of Graves' Disease Is an IgG4-Related Disease-Like Condition.

Authors:  Keiko Nagata; Sayuri Hara; Yuji Nakayama; Katsumi Higaki; Hirotsugu Sugihara; Satoshi Kuwamoto; Michiko Matsushita; Masako Kato; Shunsuke Tanio; Kiyosuke Ishiguro; Kazuhiko Hayashi
Journal:  Viral Immunol       Date:  2018-09-17       Impact factor: 2.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.